Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal stem cell and Schwann cell combination therapy for urological outcomes in complete spinal cord injury
IRCT20200502047277N4Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jul 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous bone marrow mesenchymal stromal cells in spinal cord injury (SCI) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Bladder maximum capacity, Maximum pressure of detrusor in filling and 1 more. Started Jul 2020; status: completed.
02
Drugs
autologous bone marrow mesenchymal stromal cells
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on IRCT20200502047277N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200502047277N4.